3rd ed. Oxford: Oxford University Press; 2005. 30. Gold RM, Siegel JE, Russel LB,
Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. 31. Tajima R, Kondo M, Kai H, Saito C, Okada M, Takahashi H, et al. Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clin Exp Nephrol. 2010;14:340–8.PubMedCrossRef 32. https://www.selleckchem.com/products/gkt137831.html Saito I, Kobayashi M, Matsushita Y, Mori A, Kawasugi K, Saruta T. Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res. 2008;31:1373–83.PubMedCrossRef 33. Fukuhara S, Yamazaki C, Hayashino Y, Higashi T, Eichleay MA, Akiba T, et al. The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ.
2007;7:217–31.PubMedCrossRef 34. Tsutani K, Igarashi A, this website Fujikawa K, Evers T, Kubin M, Lamotte M, et al. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med. 2007;46:157–62.PubMedCrossRef 35. Seino Y. New diagnostic criteria for diabetes in Japan. Nippon Rinsho. 2010;68:2357–61.PubMed 36. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis SGC-CBP30 order in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518–28.PubMedCrossRef 37. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19:422–37.PubMedCrossRef 38. Chrysochou C, Kalra PA. Epidemiology and natural history of atherosclerotic renovascular disease. Prog Cardiovasc Dis. 2009;52:184–95.PubMedCrossRef 39. Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong
J, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ. 2010;341:5869.CrossRef 40. Menon D, Stafinski T. Health technology MRIP assessment in Canada: 20 years strong? Value Health. 2009;12:S14–9.PubMedCrossRef 41. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–28.PubMedCrossRef 42. GISEN The Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–63.CrossRef 43. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354:359–64.PubMedCrossRef 44. Schmieder RE, Ruilope LM, Barnett AH. Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol.